Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout

Data From Second Phase III, US Filing Expected In 2024

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.